Page last updated: 2024-08-23

staurosporine and laq824

staurosporine has been researched along with laq824 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Cohen, P; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Tao, J; Vishvanath, A	1

Other Studies

1 other study(ies) available for staurosporine and laq824

Article	Year
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Exons; Flow Cytometry; fms-Like Tyrosine Kinase 3; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Time Factors; Trans-Activators	2004

Article

Year

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15

Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Exons; Flow Cytometry; fms-Like Tyrosine Kinase 3; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Proteasome Endopeptidase Complex; Protein Binding; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Staurosporine; Time Factors; Trans-Activators

2004